The research-driven biopharmaceutical company Boehringer Ingelheim announced that it will invest 120 million euros to expand and upgrade its plant in Greece.
In a press release on Thursday, the company explained that the Greece-based investment is slotted for its existing plant in Koropi, due west of the greater Athens area and near the international airport.
The funds will enable the plant to increase the manufacturing capacity of the plant in regards to new and existing medications and will add 110 new jobs.
Some of the key disease areas addressed by the medications produced by the plant include cardio-renal-metabolic (CRM) diseases, mental health and pulmonary fibrosis.
Exports of a well-known drug for type 2 diabetes, heart failure and chronic kidney disease called Jardiance will be enhanced and sent to the USA.
The ceremony where the announcement was made was attended by Greek Prime Minister Kyriakos Mitsotakis, Greek Minster of State, the Minister of Health and the Minister of Development.
